OverviewSuggest Edit

IntelGenx is a drug delivery company focused on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. More recently, the company has made the strategic decision to enter the oral film market and are in the process of implementing commercial oral film manufacturing capability. This enables IntelGenx to offer its partners a comprehensive portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, tech transfer and manufacturing scale-up, and commercial manufacturing.

HQSaint-Laurent, CA

Latest Updates

Employees (est.) (Dec 2019)48(+27%)
Revenue (FY, 2019)$742 K(-59%)
Share Price (Oct 2020)C$0.2 (-9%)
Cybersecurity ratingFMore

Key People/Management at IntelGenx

Mark Nawacki

Mark Nawacki

Andre Godin

Andre Godin

President and Chief Financial Officer
John S. Marinucci

John S. Marinucci

Horst G. Zerbe

Horst G. Zerbe

Chairman & CEO
Show more

IntelGenx Office Locations

IntelGenx has an office in Saint-Laurent
Saint-Laurent, CA (HQ)
6420 Rue Abrams
Show all (1)

IntelGenx Financials and Metrics

IntelGenx Revenue

IntelGenx's revenue was reported to be $742 k in FY, 2019

Revenue (Q2, 2020)


Net income (Q2, 2020)


EBIT (Q2, 2020)


Market capitalization (16-Oct-2020)


Closing stock price (16-Oct-2020)


Cash (30-Jun-2020)



IntelGenx's current market capitalization is C$21.4 m.
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Revenue growth, %


Sales and marketing expense


General and administrative expense

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020



Sales and marketing expense


General and administrative expense


R&D expense

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019



Accounts Receivable


Prepaid Expenses



USDQ2, 2011

Financial Leverage

1.1 x
Show all financial metrics

IntelGenx Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

IntelGenx Online and Social Media Presence

Embed Graph

IntelGenx News and Updates

IntelGenx Closes U.S.$1.2 Million Private Placement Financing

SAINT LAURENT, Quebec, Oct. 15, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) announces the closing of an offering by way of private placement (the “Offering”) to certain investors in the United States of U.S.$1.2 million principal am…

IntelGenx Amends Stock Options

SAINT LAURENT, Quebec, Aug. 24, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. ("IntelGenx", or the “Company”) (TSX-V: IGX) (OTCQB:IGXT) announced today that the Company’s board of directors amended the expiration time of Stock Options granted to Andre Godin, President and CFO, under the 20…

ATAI and IntelGenx enter into Feasibility Agreement to develop pharmaceutical-grade polymeric film technologies for delivery of psychedelic medicines

NEW YORK, Aug. 20, 2020 /PRNewswire/ -- Today, ATAI Life Sciences ("ATAI" or the "Company"), a global biotech developing psychedelic and non-psychedelic compounds for a variety of mental health indications, announced a Feasibility Agreement with IntelGenx Corp. (TSX V:IGX)(OTCQB:IGXT)...

IntelGenx Announces Approval of Proposed Amendments to Convertible Debentures

SAINT LAURENT, Quebec, June 25, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx” or the “Corporation”) today announced that the holders (“Debentureholders”) of its 8.0% convertible unsecured subordinated debentures due June 30, 2020, originally issued on …

IntelGenx Reports Fourth Quarter and Full-Year 2019 Financial Results

SAINT LAURENT, Quebec, March 26, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX V:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") today reported financial results for the fourth quarter and twelve-month periods ended December 31, 2019. All dollar amounts are expressed in U.S. currency,…

IntelGenx Announces Pricing of Equity Offering

SAINT LAURENT, Quebec, Jan. 27, 2020 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSXV: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) announced today the pricing of an agency offering (the “Offering”) of up to 20,000,000 units, subject to a minimum offering of 10,000,000 units (the “Units…
Show more

IntelGenx Frequently Asked Questions

  • When was IntelGenx founded?

    IntelGenx was founded in 2003.

  • Who are IntelGenx key executives?

    IntelGenx's key executives are Mark Nawacki, Andre Godin and John S. Marinucci.

  • How many employees does IntelGenx have?

    IntelGenx has 48 employees.

  • What is IntelGenx revenue?

    Latest IntelGenx annual revenue is $742 k.

  • What is IntelGenx revenue per employee?

    Latest IntelGenx revenue per employee is $15.5 k.

  • Who are IntelGenx competitors?

    Competitors of IntelGenx include Vitality Biopharma, Mylan and Esperion Therapeutics.

  • Where is IntelGenx headquarters?

    IntelGenx headquarters is located at 6420 Rue Abrams, Saint-Laurent.

  • Where are IntelGenx offices?

    IntelGenx has an office in Saint-Laurent.

  • How many offices does IntelGenx have?

    IntelGenx has 1 office.